الفهرس 
Mohamed Abd El-Hakim ZakiOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Panretinal photocoagulation is a well-known principal
therapy for proliferative diabetic retinopathy. Although PRP
reduces the possibility of severe visual loss, it has several side
effects, such as macular edema, constricted visual field and laserinduced
vitreous hemorrhage. Also, additional laser therapy or
surgical intervention has been necessary after PRP performance.
Recent reports have shown that VEGF plays a key role in
neovascularization of the eye, and that intravitreal anti-VEGF
injection can lead to regression of neovessels.
Anti-VEGF is effective when PRP is not possible; also
when neovascular glaucoma develops after full PRP. However, we
experienced unfavorable adverse events after injection of
bevacizumab.
Both PRP alone and bevacizimab augmented PRP are
effective in regression of neovessels with no evident difference in
BCVA , size of neovessels or central macular thickness over 12
week follow up period except that bevacizumab augmented PRP
gives faster effect in decreasing the size of neovessels however
this effect is short term.
Therefore, intravitreal bevacizumab injection may be
performed with caution until its long- term effects and safety are
confirmed in future.